Who should avoid microdosing psilocybin

The list below outlines situations where microdosing psilocybin may not be appropriate. It is indicative, not exhaustive, and individual circumstances vary.

If you are receiving medical, psychiatric or addiction care, the clinical team must be made aware of and explicitly agree to your microdosing within the context of that treatment. If you take regular medication, it is advisable to check with a clinician before starting microdosing.

We divide the information below into two sections:

  • GENERAL PROFILES — risks related to psychiatric and medical conditions, medications and drugs, side-effects, and legal or occupational factors.
  • ADDICTION PROFILES — situations linked to addictive patterns or circumstances in which microdosing for addiction may not be workable at this time.

General profiles

Risks that apply to everyone:

If pregnant or breastfeeding.

If experiencing any of these psychiatric conditions or mental-health instability:
  • Active episode or history of psychosis, psychotic disorders (schizophrenia, schizoaffective, delusional), including substance-induced psychosis.
  • Active episode or history of bipolar I.
  • Any acute destabilisation in mood, perception, or behaviour.
  • Strong family history of psychosis/bipolar disorders (first‑degree relative).
  • Severe depression, uncontrolled anxiety, or PTSD with dissociation.
  • Suicidal thoughts, plans, or impulses.
  • Any period where your mental health feels unstable or is rapidly changing.
  • Any other severe mental health crisis or acute psychiatric symptoms.


Exercise major caution and, if possible, microdose psilocybin under clinical supervision, if you have:

  • Bipolar II.
If experiencing any of these cognitive or neurodevelopmental factors:
  • Cognitive difficulties or confusion — especially problems with planning, organisation, memory or tracking — whether due to dementia, post-traumatic brain injury, severe ADHD, or any other condition.
  • OCD with poor impulse control or compulsive redosing behaviour.


Exercise major caution and, if possible, microdose psilocybin under clinical supervision, if you have:

  • Autism with severe sensory overwhelm or rigidity.
If experiencing medical conditions such as:
  • Cardiovascular risks: uncontrolled cardiovascular disease (e.g., uncontrolled hypertension, significant arrhythmia), or structural conditions (e.g., valvular disease, cardiomyopathy).
  • Seizure disorders not well controlled.
  • Eating disorders with electrolyte instability or severe malnutrition, especially active anorexia nervosa.
  • Sleep-deprivation or untreated sleep apnoea severe enough to cause cognitive lapses.
  • Any other acute medical risks.


Exercise major caution and, if possible, microdose psilocybin under clinical supervision, if you have:

  • Severe gastrointestinal disease (such as Crohn’s, ulcerative colitis flares, chronic gastritis, etc.).
  • Severe migraines, especially migraines with aura when using triptans.
If on medication or taking recreational drugs that may interact with psilocybin:
  • For a list of medications that may interact with psilocybin CHECK HERE
  • Undergoing major medication changes (starting, stopping, or switching medications).
  • Current use of serotonergic recreational drugs: MDMA, 2C-x compounds, NBOMes, methylone, and similar agents.
  • Experiencing strong or persistent side-effects of microdosing psilocybin that don’t settle despite dosage adjustments or changing the species, type, ingestion form or preparation method.
If in legal, occupational, or situational risks:
  • Safety-sensitive jobs.
  • Being subject to, or at risk of being subjected to, drug testing.
  • Immigration or visa vulnerability.
  • Where or when possession or use of psilocybin carries the risk of criminal penalties.

Addiction profiles

Risks that apply to people struggling with addiction:

Acute medical or withdrawal-related risks:
  • In an acute state due to substance misuse. Signs of liver strain, seizures, unmanaged withdrawal, or any issue where a clinician would say, “We need to see you now”.
  • In a severe withdrawal risk. The current stage of one’s addiction requires medical supervision for discontinuation or reduction.
  • During benzodiazepine dependence, particularly during withdrawal or unstable use.
  • During stimulant-induced psychosis or its history.
Safety risks to self or others:
  • If immediate safety concerns are present such as for example violence, fits of rage, neglect, endangering dependants, or active thoughts of self-harm, etc.
  • If a marked tendency towards risky behaviours is present: Placing oneself or others in dangerous situations in the context of addiction or while under the influence.
  • If a pattern of excessive spending is present to finance addictive substance use or behavioural addiction.
  • If a marked impulsivity or recklessness is present, especially an inability to abstain from taking a full dose of psilocybin when in possession of the substance.
  • If an inability to follow recommendations and instructions is present.
Treatment and contextual constraints:
  • During detox, in closed-setting treatment, or in mandated treatment, unless your treating team is aware of and explicitly agrees to your microdosing in that context.
  • In unfavourable circumstances, such as any life situation that would make preparing, storing, or accurately measuring psilocybin intake difficult.
  • With unrealistic expectations, magical-rescue fantasies, or pressure for a rapid fix.
  • If a pattern of compulsive herbal or supplement stacking is present.
  1. Get medical advice.
  2. Reach out to specialised addiction services.
  3. Stabilise in a safe setting—detox, inpatient, or outpatient.
  4. Put safeguards in place: implement family safety plans and create distance where there’s a risk of harming others. Limit access to funds and reduce exposure to high-risk environments.

Microdosing for addiction and the MESMERIC method come after all of the above.

Still not sure if microdosing psilocybin or the MESMERIC method is for you? A specialist in microdosing for addiction can offer guidance.

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *